Still, given the molecular heterogeneity in CRC (Sveen et al., 2020), including RAS/BRAF mutations, and that ASPP2 has other binding partners such as RAS (Wang et al., 2013), the precise mechanisms of ASPP2κ function remain to be elucidated. The gene discussed is BRAF; the disease is colorectal carcinoma.